The graphs make it seem so simple:
Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
